Pgp (P-glycoprotein) (ABCB1) is an ATP-powered efflux pump which can transport hundreds of structurally unrelated hydrophobic amphipathic compounds, including therapeutic drugs, peptides and lipid-like compounds. This 170 kDa polypeptide plays a crucial physiological role in protecting tissues from toxic xenobiotics and endogenous metabolites, and also affects the uptake and distribution of many clinically important drugs. It forms a major component of the blood-brain barrier and restricts the uptake of drugs from the intestine. The protein is also expressed in many human cancers, where it probably contributes to resistance to chemotherapy treatment. Many chemical modulators have been identified that block the action of Pgp, and may have clinical applications in improving drug delivery and treating cancer. Pgp substrates are generally lipid-soluble, and partition into the membrane before the transporter expels them into the aqueous phase, much like a 'hydrophobic vacuum cleaner'. The transporter may also act as a 'flippase', moving its substrates from the inner to the outer membrane leaflet. An X-ray crystal structure shows that drugs interact with Pgp within the transmembrane regions by fitting into a large flexible binding pocket, which can accommodate several substrate molecules simultaneously. The nucleotide-binding domains of Pgp appear to hydrolyse ATP in an alternating manner; however, it is still not clear whether transport is driven by ATP 1 email fsharom@uoguelph.ca
Introduction
It was observed many years ago that cultured cells exposed to increasing concentrations of cytotoxic drugs can develop resistance to their killing effects by several different mechanisms. Victor Ling's group noted that cells selected for resistance to colchicine also displayed resistance to several structurally unrelated compounds, a phenomenon known as MDR (multidrug resistance). In 1976, this resistance phenotype was linked to the presence in the plasma membrane of a 170 kDa surface glycoprotein, which they named Pgp (P-glycoprotein; also known as MDR1) for its ability to reduce the apparent cellular permeability of drugs [1] . It soon became clear that Pgp is involved in energy-dependent removal of drugs from the cell; in other words, it is an active drug-efflux pump. Following the discovery of Pgp, its expression was identified in normal tissues, as well as many cultured cells of mammalian and human origin, including 39 of 60 tumour cell lines used by the U.S. National Cancer Institute in the discovery of new anti-cancer drugs [2] . Pgp is now the most studied and well-understood transporter in the ABC (ATP-binding cassette) superfamily. Pgp genes have been sequenced from human, mouse and Chinese hamster, among others, and homologues have been identified in many other species, including Caenorhabditis elegans and Drosophila melanogaster.
Tissue distribution and physiological role of Pgp
Although Pgp is expressed in most human and rodent tissues at low levels, it is found in much higher amounts at the apical surface of epithelial cells of the large and small intestine, liver bile ductules and kidney proximal tubules [3] , which all have excretory roles. The transporter is also found in the adrenal gland, the placenta and the apical membrane of endothelial cells lining the capillaries of the brain. These cells form a continuous monolayer, the so-called blood-brain barrier, which stops blood components from crossing into the central nervous system. Pgp is oriented in these cells to transport substrates towards the blood, and is thus a major factor in limiting their entry to the brain [4] . Similarly, it appears to play a central role in protecting the fetus and other sensitive tissues from the toxicity of a variety of endogenous and exogenous molecules. This proposal is supported by studies on transgenic knockout mice lacking Pgp (rodents have two Pgp genes, Abcb1a and Abcb1b, so both must be inactivated). These animals have a normal lifespan and appear healthy and fertile. However, when Pgp substrates are administered to them, the drugs accumulate to very high levels in the brain compared with wild-type mice, resulting in neurotoxicity [5] . For example, Pgp-knockout mice are 100-fold more sensitive to the toxicity of ivermectin, a pesticide commonly used in mouse colonies.
Pgp is now known to affect the disposition of many clinically administered drugs (discussed in more detail below), and makes a major contribution to ADME (absorption, distribution, metabolism, excretion). In the intestine, Pgp is responsible for extrusion of drugs into the lumen, thus reducing their absorption and oral bioavailability. As expected, Pgp-knockout mice display increased uptake of substrates from the digestive tract and markedly slower elimination from the circulation, which, for some drugs, leads to dramatically increased toxicity. Pgp-knockout mice have proved very useful for identifying or confirming drugs as substrates for the transporter in vivo. For the most part, species differences between mouse and human with respect to Pgp substrate specificity appear to be small.
Certain lineages of collie and other dog breeds have a frameshift mutation in the Pgp gene, rendering the protein non-functional; they are also highly sensitive to ivermectin toxicity. Despite the widespread clinical use of drugs that are Pgp substrates, there have been no reports so far of non-functional Pgp variants in humans.
In addition to providing protection from harmful xenobiotics, Pgp may play a role in the transport of endogenous molecules and metabolites [6] . Possible endogenous substrates include phospholipids and glycolipids, platelet-activating factors, amyloid β-peptides and small cytokines such as interleukins. Pgp may also export steroid hormones such as aldosterone and progesterone from the adrenal gland and the uterine epithelium. However, little information is available on the extent of Pgp-mediated transport of these endogenous molecules in vivo.
Close relatives of Pgp: ABCB4 and ABCB11
The human ABCB4 and ABCB1 genes are located adjacent to each other, and arose from a gene-duplication event. The two proteins are closely related (78% sequence identity), which suggests that they probably share similar structures and mechanisms of action. The ABCB4 protein (formerly known as MDR3 in human and Mdr2 in rodents) is a lipid translocator, which carries out export of PC (phosphatidylcholine) from the apical (canalicular) membrane of hepatocytes into the bile [7] . PC present in the bile forms mixed micelles with bile salts, which otherwise cause cellular damage because of their detergent-like properties. Transgenic knockout mice lacking ABCB4 do not excrete any PC into the bile [8] . The physiological function of ABCB4 is crucial to human health, and a deficiency leads to progressive familial intrahepatic cholestasis type 3, a severe liver disease resulting from decreased bile flow [9] . ABCB4 probably operates as an outwardly directed 'flippase', moving PC from the inner to the outer leaflet of the hepatocyte plasma membrane, where it can be extracted into the canalicular lumen by bile salts. As we will see below, Pgp also demonstrates lipid flippase activity.
In 1995, another close relative of Pgp was identified, and named Spgp (sister of P-glycoprotein). This protein, which is only expressed in the liver, turned out to function as an ATP-dependent bile-salt-export pump and was thus renamed BSEP (ABCB11) [10] . Inherited mutations in ABCB11 result in severe cholestatic liver disease arising from reduced bile salt secretion. Certain polymorphisms in ABCB11 appear to result in the protein being more susceptible to inhibition by drugs, thus causing acquired cholestasis.
Pgp substrates and modulators
Pgp can interact with a vast array of compounds that are structurally unrelated, including natural products, chemotherapeutic drugs, steroids, linear and cyclic peptides, fluorescent dyes and ionophores. Most are weakly amphipathic and relatively hydrophobic, often (but not always) containing aromatic rings and a positively charged N atom. However, direct measurement of transport has been carried out for only a few of these putative substrates, and most have been identified on the basis of resistance of Pgp-overexpressing cell lines to their cytotoxic effects. Table 1 lists some of the different classes of Pgp substrates, and Figure 1 shows representative structures. A second group of compounds can also interact with Pgp, known as modulators (also called inhibitors or chemosensitizers) [11] . Modulators are able to reverse MDR in intact cells by interfering with the ability of Pgp to efflux drugs. Like substrates, Pgp modulators are structurally diverse (Figure 1 ), and many have been identified over the years (see Table 2 ). Modulators may inhibit Pgp transport function in a number of ways, and their mode of action at the molecular level is not well understood. Some are transported themselves (e.g. cyclosporin A [12] ), and thus act as competing substrates, whereas others (e.g. LY335979 [13] ) bind tightly to the protein's drug-binding pocket for prolonged periods of time without being transported. A few modulators appear to interact with the NBDs (nucleotide-binding domains) (e.g. steroids or disulfiram [14] ) and interfere with ATP hydrolysis. Several membrane Essays in Biochemistry volume 50 2011 Benzyl alcohol fluidizers and surfactants (e.g. benzyl alcohol, Nonidet P40 or Cremaphor EL [15] ) do not appear to directly interact with Pgp, and probably act as non-specific modulators at the level of the membrane bilayer. Pgp modulators may be valuable for their ability to increase delivery of therapeutic drugs to the brain [16] , which is desirable in the treatment of diseases such as cancer, AIDS, Alzheimer's disease, Parkinson's disease, schizophrenia and epilepsy.
Structure of Pgp
Pgp is a single polypeptide made up of two homologous halves that arose from gene duplication. Each half comprises six TMHs (transmembrane helices) and one NBD located on the cytoplasmic side of the membrane, which are connected by a cytoplasmic linker ( Figure 2A ). This topology has been confirmed by cysteine mutagenesis and epitope-insertion experiments. The structure of Pgp was first studied by EM (electron microscopy), and the highest resolution structure [8 Å, (1 Å=0.1 nm); see Figure 2B ], confirmed the presence of 12 TMHs and two closely associated NBDs [17] . In 2009, X-ray crystal structures (3.8-4.4 Å) of mouse Pgp were reported [18] , both in the absence of substrate, and with two stereoisomeric cyclic hexapeptide inhibitors bound to the transporter ( Figures 2C and 2D ). Two interdigitated bundles of α-helices were observed, each made up of portions from both the N-terminal and C-terminal halves (TMHs 1-3, 6, 10 and 11, and TMHs 4, 5, 7-9 and 12). The long intracellular loops of one helix bundle contact the opposing NBD. This crossover between the two halves of the transporter is also seen in the crystal structure of the bacterial transporters Sav1866 [19] and MsbA [20] . The two bundles of TMHs enclose a very large (6000 Å 3 ) cavity which can accommodate at least two substrate molecules simultaneously. This cavity is contained within the membrane and is open to the inner leaflet via 'portals', probably to allow drug entry from the lipid bilayer. The QZ59-RRR and QZ59-SSS peptide stereoisomers bind to distinct subsites in the binding cavity in different orientations, and make different sets of contacts with amino acid side chains of the protein. QZ59-RRR binds to a 'middle' site, held in place by favourable hydrophobic interactions with phenylalanine, tyrosine, leucine and isoleucine residues ( Figure 2D ). On the other hand, two molecules of QZ5-SSS are found in different locations, 'upper' and 'lower' sites, within the binding pocket ( Figure 2D ), and some polar residues are involved in interactions with the latter. Thus Pgp appears to bind multiple drugs by having a large highly flexible binding cavity which can accommodate many compounds in different locations by an 'induced fit' type of mechanism. Biochemical cross-linking and fluorescence studies had already pointed to a substrate-binding region with these properties [21, 22] . The polyspecific nature of the Pgp-binding pocket and its ability to bind more than one drug molecule simultaneously makes the rational design of specific high-affinity inhibitors a challenging problem.
Drug pumping by Pgp
Characteristics of Pgp-mediated drug transport Because cytotoxic Pgp substrates are generally lipophilic, they can enter cells readily by passive diffusion across the plasma membrane and then bind to their cellular target, which could be (for example) microtubules or DNA. Early studies using drug-selective MDR cell lines expressing Pgp showed that cellular drug accumulation was greatly reduced compared with the parent drug-sensitive cell line, and similar observations were also made for cells transfected with the ABCB1 gene. Lower drug accumulation was observed to require cellular energy. Treatment with Pgp modulators reversed drug resistance and restored both higher drug accumulation and cytotoxicity, with the drug dose-response curve often moving to 50-100-fold lower concentrations in the presence of a compound such as verapamil. Such changes in drug uptake can be conveniently observed in intact cells using flow cytometry with fluorescent Pgp substrates, such as daunorubicin or rhodamine 123 (e.g. [23] ).
Intact cell systems proved to be too complex for dissection of the biochemical details of drug transport, and studies were soon initiated using plasma membrane vesicles isolated from MDR cells expressing Pgp. Inside-out vesicles transport drugs into the vesicle interior in vitro when supplied with ATP in the external medium, thus generating a drug concentration gradient across the membrane, which is collapsed by inhibitors (e.g. [24] ). Purified Pgp reconstituted into proteoliposomes can similarly transport drugs into the interior of the vesicle. Transport is observed to be saturable, requires ATP hydrolysis and is inhibited by other transport substrates and modulators (e.g. [25, 26] ). However, unexpected allosteric interactions are also observed between transported substrates. For example, Hoechst 33342 stimulates the transport of rhodamine 123 and vice versa [27] , probably because the two drugs bind simultaneously to different subsites within the binding pocket. Such complex drug-drug interactions may be an important consideration in clinical therapy, where two Pgp substrates are often co-administered.
Hydrophobic vacuum cleaner or lipid flippase?
Compounds that interact with Pgp are relatively hydrophobic and readily soluble in lipid bilayers, and it is now widely accepted that they partition into the membrane before interacting with the protein. Thus Pgp has been described as a 'hydrophobic vacuum cleaner' [28] that expels lipophilic molecules from the membrane into the extracellular medium (Figure 3 ). This pumping action gives rise to a concentration gradient across the plasma membrane, with a higher drug concentration in the external aqueous phase. The transporter is able to intercept substrates before they have an opportunity to enter the cytosol, thus protecting the cell from exposure to potentially toxic molecules. These ideas are supported by the Pgp X-ray crystal structures, which show that two peptide stereoisomers are bound deep within the TMHs, suggesting that they may gain access to the protein from within the lipid bilayer [18] . Pgp binds lipid-like drugs and platelet-activating factor [29] , which may be a physiological substrate [30] , and it also translocates fluorescently labelled phospholipids across the membrane in an ATP-dependent fashion [31] . Thus the protein may function as a translocase or 'flippase' for lipophilic molecules [28] (Figure 3) , moving them from the cytoplasmic to the extracellular membrane leaflet. Given the high level of sequence similarity between Pgp and its close relative ABCB4, which is a PC flippase, it is perhaps not surprising that they share some functional attributes. The rate of spontaneous transbilayer movement of many Pgp substrates is relatively low, and since they appear to localize discretely to one membrane leaflet, the transporter would be able to maintain a higher drug concentration in the outer leaflet. This flippase activity would also give rise to a substrate concentration gradient across the membrane, since drug in the outer leaflet would rapidly equilibrate with the external medium. However, because of the rapid partitioning equilibria involved, it is very difficult to distinguish between flippase activity and direct transport of drug from the membrane to the extracellular aqueous phase.
ATPase catalytic cycle
Drug transport by Pgp is powered by hydrolysis of ATP at the two cytoplasmic NBDs, which are characterized by three highly conserved sequence motifs [32] . The Walker A and B motifs are found in many proteins that bind and hydrolyse ATP and GTP, and the signature C motif is unique to the ABC superfamily. Structural studies on bacterial ABC proteins led to the now generally accepted concept that the NBDs must dimerize in order to hydrolyse ATP [33] . In this so-called 'ATP sandwich dimer', the NBDs are arranged in a head-to-tail arrangement, with two ATP molecules bound along the interface. Each nucleotide is held in place by the Walker A and B motifs of one NBD and the signature C motif of the other NBD, which thus form a composite binding site [34] . The Pgp crystal structure does not contain bound nucleotide, and since the two NBDs are separated by 30 Å [18] , it does not provide any useful information about the putative dimerization process. However, the signature C and Walker A motifs are known to be close to each other from cross-linking studies [35] .
It is not well understood how ATP hydrolysis is co-ordinated between the two NBDs, or how this energy is used to drive drug transport [36] . Drug binding to Pgp alters its basal ATPase activity, which is relatively high even in the apparent absence of substrates. Some drugs stimulate ATPase activity, whereas others inhibit it, and a biphasic pattern of stimulation at low concentrations and inhibition at higher concentrations is common. It is still not known whether Pgp hydrolyses one or two molecules of ATP for each drug molecule it transports.
Some important mechanistic insights were provided by the use of orthovanadate (V i ), an inorganic phosphate analogue. Addition of V i and ATP to Pgp leads to very rapid loss of ATPase activity. After a single catalytic turnover, P i dissociates and V i takes its place, leading to 'trapping' of the stable complex ADP·V i ·Mg 2+ in one NBD [37] . The V i -trapped complex is very stable, and its structure is thought to resemble that of the pentaco-ordinate catalytic transition state. Since trapping of V i in one NBD abolishes catalytic activity at the other, this suggests that both active sites must be functional for ATP hydrolysis to occur. This observation led to the proposal of the 'alternating sites' mechanism, in which only one NBD is catalytically active at any instant in time, and the two active sites take turns in hydrolysing ATP [38] .
Transport cycle
In special circumstances where nucleotide hydrolysis is blocked {for example, after inactivation of the NBDs by mutation, or the use of the poorly hydrolysable analogue ATPγS (adenosine 5´-[γ-thio]triphosphate)}, it has been possible to isolate a Pgp intermediate with one very tightly bound nucleotide ('occluded') and one loosely bound nucleotide [39] [40] [41] . This species probably represents the E·S (enzyme·substrate) intermediate normally present immediately before ATP hydrolysis occurs. The tightly bound ATP is assumed to have a 'closed' dimer interface (Figure 4) , and in the case of an active protein with bound ATP, it would progress rapidly to the transition state, leading to ATP hydrolysis. In contrast, the dimer interface around the loosely bound nucleotide is likely to be 'open'. This information led to the proposal of a model in which Pgp always exists in an asymmetric state, with one closed (high-affinity) active site and one open (low-affinity) active site (Figure 4) . The tightly bound ATP molecule is committed to enter the transition state and undergo hydrolysis. Simultaneous switching of the affinities as a result of ATP hydrolysis would result in alternation of catalysis between the two NBDs. Movement of drug across the membrane may be driven by the energy released during ATP hydrolysis, and would involve switching from an inward-facing conformation with high drug-binding affinity to an outward-facing conformation with low drug-binding affinity (Figure 4 ). Other models for the mechanism of ABC transporters have been proposed (see Chapter 4) in which ATP binding alone drives drug transport (ATP switch model [42] ), or two ATP molecules are hydrolysed sequentially to open both halves of the NBD dimer interface (processive clamp model [43] ). Clearly, more work will be needed to clarify the mechanistic details of how the NBDs of Pgp hydrolyse ATP, and how drug transport is powered.
Importance of Pgp in drug therapy and disease
Interactions with clinically used drugs Pgp interacts with many drugs in widespread clinical use (see Table 1 ), including a large number of anticancer drugs, anti-histamines, immunosuppressive agents, anti-epileptics, cardiac glycosides, anti-hypertensives, HIV protease inhibitors, Ca 2+ channel blockers, antibiotics and cholesterol-lowering statins (for a review, see [44] ). The clinical effectiveness of these drugs is greatly affected . The catalytically active pump rapidly progresses to the asymmetric state in which one ATP molecule is tightly bound (ATP T ) in one NBD, where the dimer interface is 'closed'. The tightly bound ATP molecule is committed to enter the transition state and undergoes hydrolysis, which provides the energy for movement of drug (red sphere) from the binding pocket within the transporter to the extracellular space. Drug transport probably involves a conformational change from an inward-facing to an outward-facing protein conformation. After ATP hydrolysis, ADP is loosely bound (ADP L ), resulting in opening of the dimer interface. The other catalytic site simultaneously switches to the high-affinity state, resulting in tight binding of the second ATP molecule and closure of the dimer interface in the other NBD. P i then dissociates from the catalytic site of the first NBD, followed by ADP, which is replaced by another molecule of loosely bound ATP (nucleotide exchange) to achieve the asymmetric state again. A second round of ATP hydrolysis and drug transport then takes place at the other NBD. Pgp exists in an asymmetric state at all stages of the catalytic cycle, thus requiring that the two NBDs alternate in hydrolysing ATP. Adapted from [40] with permission. © 2010 American Society for Biochemistry and Molecular Biology.
by Pgp, which alters their absorption and tissue distribution [45] . Interaction of a drug with Pgp can cause poor uptake in the intestine, thus reducing oral bioavailability, and prevent delivery of drugs to the brain, which is a serious problem in the treatment of brain diseases. The co-administration of two drugs that are both Pgp substrates can also lead to major pharmacokinetic effects as they compete for the transporter [46] . Plasma drug levels stay higher for longer, and a reduction in drug dose is often necessary to avoid toxicity. Similar effects are observed when a Pgp substrate drug is consumed with foods or herbal supplements containing natural products that are also Pgp substrates (e.g. plant flavonoids, St John's wort [47] ). For these reasons, drug testing for Pgp interactions is now recommended by the U.S. FDA (Food and Drug Administration) as part of its approval process [48] . Such tests are usually carried out using polarized monolayers of epithelial cell lines either transfected with human Pgp, or expressing Pgp naturally. Movement of the test compound from the medium on the basolateral side of the monolayer to the medium on the apical side (B→A, passive diffusion plus Pgp-mediated efflux) is compared with movement in the opposite direction (A→B, passive diffusion only). This is a time-consuming and expensive assay, and there is currently a pressing need for new rapid high-throughput methods.
Over 50 polymorphisms (single nucleotide polymorphisms and insertions/deletions) in the ABCB1 gene are known [49] , and some of them appear to change the mRNA expression, protein expression and function of Pgp. Polymorphisms may be responsible for the variation in drug responses observed between different individuals and populations, and, in recent years, there has been considerable interest in how they might affect the outcome of drug therapy in people carrying them. However, there have been many conflicting reports in this field, and no clear associations between genotype and altered response to drug treatment have emerged [44] . Similarly, polymorphisms have been reported to alter the susceptibility of certain individuals to various disease states, including colon cancer, renal cancer, inflammatory bowel disease and Parkinson's disease (reviewed in [44] ). This is a rapidly developing field, and will require substantial further investigation before firm conclusions can be reached.
Pgp in drug discovery
The presence of Pgp in the intestinal epithelium is a serious problem in drug discovery, since new drug candidates may be poorly absorbed, making them ineffective clinically. It is especially important to screen out Pgp substrates when developing drugs targeted to the brain, since their efficacy depends on their ability to cross the blood-brain barrier. Many pharmaceutical companies now routinely include testing for interactions with Pgp as part of their drug discovery process. Methods that are employed range from measurements of drug uptake in intact cells to in vitro assays that assess the effect of a compound on Pgp ATPase or transport activity in membrane vesicles [50] . Predictive methods have been of limited value in determining whether a compound is likely to be a substrate for Pgp, although this may change as we gain a better understanding of its drug-binding pocket.
Resistance to chemotherapy treatment
Resistance of tumours to the cytotoxic action of chemotherapy drugs is the single most common cause of cancer treatment failure. Some cancers, including tumours of the kidney, liver, breast and ovary, are drug-resistant at the outset (intrinsic resistance), whereas others, typically leukaemias, lymphomas and multiple myeloma, develop resistance after one or more rounds of chemotherapy treatment (acquired resistance). For several cancers, including AML (acute myelogenous leukaemia), ALL (acute lymphoblastic leukaemia) and ovarian tumours, high Pgp expression levels are strongly linked to a weak response to chemotherapy treatment and poor overall prognosis [51, 52] . However, in other cases, it has proved difficult to link MDR in cancer to Pgp expression, probably because there are multiple mechanisms by which some tumours can develop drug resistance.
There has been much interest in combining modulators with chemotherapy drugs to improve the outcome of cancer treatment [53] . However, only a few of the hundreds of compounds identified as modulators in vitro proved suitable for use in clinical trials [54] (Table 2) . First-generation modulators, which were already in use for other medical conditions (e.g. verapamil), were tested in the 1980s and generally proved too toxic to patients. They were modified to produce second-generation compounds, which often showed adverse pharmacokinetic interactions in which decreased clearance of anti-cancer agents led to toxicity. In recent years, more rationally designed third-generation modulators of low toxicity have been produced, which are highly selective and potent inhibitors of Pgp transport function. One notable success has been the combined use of modulators and chemotherapy to cure childhood retinoblastoma [55] . However, the results of clinical trials using Pgp modulators in cancer treatment have generally been disappointing [51, 53, 54] , possibly because these studies suffered from serious experimental limitations such as poor patient selection criteria. There is current interest in exploring the use of natural components of foods/ plants as Pgp modulators (e.g. flavonoids, curcuminoids; see Table 2 ), and they could serve as useful leads for the development of fourth-generation agents [54] .
Conclusions
This chapter provides a brief overview of what we currently know about the structure, function and mechanism of the Pgp drug-efflux pump. This transporter is of central importance in protecting sensitive tissues from toxic xenobiotics and can also interfere with the delivery of clinically used drugs. As indicated, rapid progress has been made in recent years in elucidating the three-dimensional structure and ATP-hydrolysis cycle of Pgp. However, much remains to be learned in understanding how so many different compounds interact with the protein's flexible substrate-binding pocket, and how ATP hydrolysis powers drug transport. The many molecular tools now at our disposal should provide insights into the involvement of this fascinating protein in both normal human physiology and drug delivery. Such information may lead to the development of novel approaches to manipulate Pgp function in a way that will improve the outcome of clinical therapy. 
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